DNLI
Denali Therapeutics Inc

1,697
Loading...
Loading...
News
all
press releases
Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report?
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·23d ago
News Placeholder
More News
News Placeholder
DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26
Denali Therapeutics posts narrower-than-expected Q2 loss. The company advances multiple rare disease therapies toward potential approvals.
Zacks·2mo ago
News Placeholder
Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?
CPRX gears up to report Q2 results as Firdapse sales rise, Agamree grows, and Fycompa faces a post-patent dip.
Zacks·2mo ago
News Placeholder
Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue?
AMGN eyes another earnings beat as strong drug volumes offset pricing pressure and biosimilar headwinds.
Zacks·2mo ago
News Placeholder
DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review
Denali's lead drug for Hunter syndrome wins FDA Priority Review, marking a key step toward commercial-stage status.
Zacks·3mo ago
News Placeholder
Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report?
Zacks·4mo ago
News Placeholder
Deutsche Bank initiates coverage of biopharma stocks, sees 'modest recovery'
Investing.com -- Deutsche Bank initiated coverage on 11 U.S. biopharma stocks in a note Tuesday, assigning Buy ratings to eight companies and Hold ratings to three. 
investing.com·8mo ago
News Placeholder
These Stocks Are Moving the Most Today: Nvidia, Micron, Uber, FuboTV, Inari Medical, Denali Therapeutics, and More
These Stocks Are Moving the Most Today: Nvidia, Micron, Uber, FuboTV, Inari Medical, Denali Therapeutics, and More...
Yahoo! Finance: News·9mo ago
News Placeholder
Denali Therapeutics Stock Is Sliding After The Bell: Here's Why
Denali Therapeutics shares are moving lower in Thursday's after-hours session after the company announced that its Phase 2 study of oditrasertib was discontinued. read more...
Benzinga·1y ago
News Placeholder
Denali Outperforms Industry in 3 Months: Here's Why
Denali Therapeutics Inc. (NASDAQ: DNLI) is having a good run in 2024. Shares of this biopharmaceutical company have risen 11.9% in the past three months against the industry's decline of 6%. read more...
Benzinga·1y ago

Latest DNLI News

View

Advertisement|Remove ads.

Advertisement|Remove ads.